NEW YORK, Oct. 23, 2017 /PRNewswire/
-- ThyroSeq® presented the results of its prospective,
double-blind, multi-center international study today, at the
87th Annual Meeting of the American Thyroid
Association (ATA) in Victoria, BC,
Canada. The results of the study
provided clinical validation of the performance of ThyroSeq
V3® in thyroid nodules with indeterminate cytology. A
clinical oral presentation and a poster presentation demonstrated
that ThyroSeq's V3 is an effective tool for a definitive diagnosis
that can help to prevent the largest number of diagnostic thyroid
surgeries for patients with thyroid nodules, thus providing the
most cost-effective patient care.
"These exciting findings have been rigorously validated in
multiple clinical centers in the U.S. and abroad," said Yuri
Nikiforov, M.D., Ph.D., Professor of Pathology at University
of Pittsburgh Medical Center, and principal investigator of
the multi-center ThyroSeq V3 trial. "Every indication is that based
on the cutting-edge genomic science we'll be able to avoid surgery
for more than 60% of patients with thyroid nodules that had
indeterminate cytology and offer more effective, individualized
management for those patients that likely have cancerous thyroid
nodules."
The study shows that ThyroSeq V3 provides reliable performance
across various types of cancerous and benign thyroid nodules and in
populations with variable disease prevalence, making it a robust
tool for clinical use.
Key findings of the study include:
- ThyroSeq V3 has both very high sensitivity and high specificity
and therefore can be used as a "rule-out" and "rule-in" test for
cancer in thyroid nodules.
- ThyroSeq V3 implementation into clinical practice can lead to
avoiding surgery for more than 60% of patients with thyroid nodules
that had indeterminate cytology.
- ThyroSeq V3 provides additional valuable prognostic
information, informing the most optimal, personalized surgery for
cancerous nodules.
- ThyroSeq V3 offers all of the benefits of V2 and expands them
further with a larger gene panel and its validation in a
prospective, blinded, multicenter study.
About ThyroSeq
ThyroSeq is a joint
partnership between UPMC and CBLPath. ThyroSeq is an
innovative test for thyroid nodules and cancer. With a 10-year
history of continuous refinement, it incorporates all major
scientific discoveries and utilizes advanced technology to provide
the most accurate diagnosis of benign or malignant disease in
thyroid nodules. For more information,
visit ThyroSeq online.
About CBL Pathology
CBLPath, Inc. is a leading
provider of sub-specialized anatomic pathology and molecular
diagnostic laboratory services. For more information, please
visit www.cblpath.com
Media Contact:
Jeanine Wilson
(845) 548-1211
thyroseq@wmediagroup.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/thyroseq-announces-results-of-large-multi-center-study-validating-new-thyroseq-v3-test-at-the-american-thyroid-association-meeting-in-victoria-bc-canada-300541263.html
SOURCE ThyroSeq